(NASDAQ:MNKD) is trading unchanged by 0.15% at $3.24 giving it a place as a top gainer in the market today. 1 shares have been traded.
Traders are more bearish lately if you watch the rise in short interest. The firm recorded a rise in short interest of 11.26% as of October 13, 2017 from the last reporting period. Short interest grew from 23,671,860 to 26,337,802 over that timeframe. With short interest at 26,337,802 and short average daily volume at 27,541,901, days to cover is 1.0 and the short interest percentage is 0.23% as of October 13.
These firms have modified their investment in MNKD. As of quarter end Hanson Mcclain, Inc. had disposed of 3,000 shares trimming its position 85.7%. The value of the investment in MNKD went from $2,000 to $0 a change of 100.0% since the last quarter. As of the end of the quarter Canada Pension Plan Investment Board had sold a total of 110,500 shares trimming its holdings by 55.7%. The value of the company’s investment in Mannkind Corporation decreased from $126,000 to $54,000 a change of $72,000 for the reporting period.
Harel Insurance Investments & Financial Services Ltd. divested its holdings by selling 2,460,000 shares a decrease of 83.4% from 12/31/2016 to 03/31/2017. Harel Insurance Investments & Financial Services Ltd. now holds 490,000 shares valued at $725,000. The value of the position overall is down by 61.6%.
On November 8 HC Wainwright held the stock rating at “Buy” with a current price target of $7.00. November 1 investment analysts at Maxim Group reiterated a “Hold” rating on the stock.
On October 24, 2017 HC Wainwright reiterated a “Buy” rating on the company. On October 10 analysts at HC Wainwright updated its forecast on MNKD with a rating of “Buy”.
On September 1, 2017 Maxim Group kept a “Buy” rating on the company.
The most current P/E ratio is N/A and the market value is 372.77M. In the latest earnings report the EPS was $-0.27 with 114.87M shares now outstanding.
MannKind Corporation (MannKind), launched on February 14, 1991, is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Business’s product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control..